Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 138

Similar articles for PubMed (Select 7568175)

1.

Membrane-associated CD19-LYN complex is an endogenous p53-independent and Bc1-2-independent regulator of apoptosis in human B-lineage lymphoma cells.

Myers DE, Jun X, Waddick KG, Forsyth C, Chelstrom LM, Gunther RL, Tumer NE, Bolen J, Uckun FM.

Proc Natl Acad Sci U S A. 1995 Oct 10;92(21):9575-9. Erratum in: Proc Natl Acad Sci U S A 1996 Feb 6;93(3):1357.

2.

Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases.

Uckun FM, Evans WE, Forsyth CJ, Waddick KG, Ahlgren LT, Chelstrom LM, Burkhardt A, Bolen J, Myers DE.

Science. 1995 Feb 10;267(5199):886-91.

PMID:
7531365
3.

Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor.

Uckun FM, Messinger Y, Chen CL, O'Neill K, Myers DE, Goldman F, Hurvitz C, Casper JT, Levine A.

Clin Cancer Res. 1999 Dec;5(12):3906-13.

4.

Engagement of the CD19 receptor on human B-lineage leukemia cells activates LCK tyrosine kinase and facilitates radiation-induced apoptosis.

Waddick KG, Chae HP, Tuel-Ahlgren L, Jarvis LJ, Dibirdik I, Myers DE, Uckun FM.

Radiat Res. 1993 Dec;136(3):313-9.

PMID:
7506428
5.

In vivo toxicity and pharmacokinetic features of B43 (anti-CD19)-genistein immunoconjugate in nonhuman primates.

Messinger Y, Yanishevski Y, Ek O, Zeren T, Waurzyniak B, Gunther R, Chelstrom L, Chandan-Langlie M, Schneider E, Myers DE, Evans W, Uckun FM.

Clin Cancer Res. 1998 Jan;4(1):165-70.

6.
8.
9.

In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency.

Uckun FM, Manivel C, Arthur D, Chelstrom LM, Finnegan D, Tuel-Ahlgren L, Irvin JD, Myers DE, Gunther R.

Blood. 1992 May 1;79(9):2201-14.

10.

Clinical pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-Genistein in patients with B-lineage lymphoid malignancies.

Chen CL, Levine A, Rao A, O'Neill K, Messinger Y, Myers DE, Goldman F, Hurvitz C, Casper JT, Uckun FM.

J Clin Pharmacol. 1999 Dec;39(12):1248-55.

PMID:
10586390
11.

In vivo toxicity and pharmacokinetic features of B43(Anti-CD19)-Genistein immunoconjugate.

Ek O, Yanishevski Y, Zeren T, Waurzyniak B, Gunther R, Chelstrom L, Chandan-Langlie M, Schneider E, Myers DE, Evans W, Uckun FM.

Leuk Lymphoma. 1998 Jul;30(3-4):389-94.

PMID:
9713969
12.

In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against BCL-1 murine B-cell leukemia.

Uckun FM, Chelstrom LM, Irvin JD, Finnegan D, Gunther R, Young J, Kuebelbeck V, Myers DE, Houston LL.

Blood. 1992 May 15;79(10):2649-61.

13.

A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies.

Gidlöf C, Dohlsten M, Lando P, Kalland T, Sundström C, Tötterman TH.

Blood. 1997 Mar 15;89(6):2089-97.

14.

Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins.

Uckun FM, Jaszcz W, Ambrus JL, Fauci AS, Gajl-Peczalska K, Song CW, Wick MR, Myers DE, Waddick K, Ledbetter JA.

Blood. 1988 Jan;71(1):13-29.

15.
16.

Lyn tyrosine kinase signals cell cycle arrest but not apoptosis in B-lineage lymphoma cells.

Scheuermann RH, Racila E, Tucker T, Yefenof E, Street NE, Vitetta ES, Picker LJ, Uhr JW.

Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4048-52.

18.

In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor.

Uckun FM, Narla RK, Zeren T, Yanishevski Y, Myers DE, Waurzyniak B, Ek O, Schneider E, Messinger Y, Chelstrom LM, Gunther R, Evans W.

Clin Cancer Res. 1998 May;4(5):1125-34.

19.
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk